Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle
1
,
Joan Massague
2
1
Publication type: Journal Article
Publication date: 2019-04-16
scimago Q1
wos Q1
SJR: 12.163
CiteScore: 40.8
Impact factor: 26.3
ISSN: 10747613, 10974180
PubMed ID:
30995507
Infectious Diseases
Immunology
Immunology and Allergy
Abstract
Transforming growth factor (TGF)-β is a crucial enforcer of immune homeostasis and tolerance, inhibiting the expansion and function of many components of the immune system. Perturbations in TGF-β signaling underlie inflammatory diseases and promote tumor emergence. TGF-β is also central to immune suppression within the tumor microenvironment, and recent studies have revealed roles in tumor immune evasion and poor responses to cancer immunotherapy. Here, we present an overview of the complex biology of the TGF-β family and its context-dependent nature. Then, focusing on cancer, we discuss the roles of TGF-β signaling in distinct immune cell types and how this knowledge is being leveraged to unleash the immune system against the tumor.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
20
40
60
80
100
120
|
|
|
Frontiers in Immunology
105 publications, 5.56%
|
|
|
Cancers
63 publications, 3.34%
|
|
|
International Journal of Molecular Sciences
54 publications, 2.86%
|
|
|
Frontiers in Oncology
52 publications, 2.75%
|
|
|
Cells
29 publications, 1.54%
|
|
|
Frontiers in Cell and Developmental Biology
27 publications, 1.43%
|
|
|
Nature Communications
27 publications, 1.43%
|
|
|
Journal for ImmunoTherapy of Cancer
24 publications, 1.27%
|
|
|
International Immunopharmacology
20 publications, 1.06%
|
|
|
Biomedicines
18 publications, 0.95%
|
|
|
Journal of Translational Medicine
18 publications, 0.95%
|
|
|
Frontiers in Genetics
15 publications, 0.79%
|
|
|
Journal of Hematology and Oncology
14 publications, 0.74%
|
|
|
Scientific Reports
14 publications, 0.74%
|
|
|
Cell Death and Disease
14 publications, 0.74%
|
|
|
Heliyon
14 publications, 0.74%
|
|
|
Cancer Letters
14 publications, 0.74%
|
|
|
Advanced Science
14 publications, 0.74%
|
|
|
Cancer Immunology, Immunotherapy
13 publications, 0.69%
|
|
|
Oncogene
12 publications, 0.64%
|
|
|
iScience
12 publications, 0.64%
|
|
|
Signal Transduction and Targeted Therapy
11 publications, 0.58%
|
|
|
Cell Reports
10 publications, 0.53%
|
|
|
Cancer Research
10 publications, 0.53%
|
|
|
Biomolecules
9 publications, 0.48%
|
|
|
Journal of Experimental and Clinical Cancer Research
9 publications, 0.48%
|
|
|
Biomedicine and Pharmacotherapy
9 publications, 0.48%
|
|
|
Cancer Discovery
9 publications, 0.48%
|
|
|
OncoImmunology
9 publications, 0.48%
|
|
|
20
40
60
80
100
120
|
Publishers
|
50
100
150
200
250
300
350
400
450
|
|
|
Elsevier
413 publications, 21.86%
|
|
|
Springer Nature
383 publications, 20.28%
|
|
|
Frontiers Media S.A.
232 publications, 12.28%
|
|
|
MDPI
223 publications, 11.81%
|
|
|
Wiley
141 publications, 7.46%
|
|
|
Cold Spring Harbor Laboratory
72 publications, 3.81%
|
|
|
Taylor & Francis
67 publications, 3.55%
|
|
|
American Association for Cancer Research (AACR)
41 publications, 2.17%
|
|
|
BMJ
25 publications, 1.32%
|
|
|
American Chemical Society (ACS)
20 publications, 1.06%
|
|
|
Hindawi Limited
18 publications, 0.95%
|
|
|
Spandidos Publications
16 publications, 0.85%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
15 publications, 0.79%
|
|
|
American Association for the Advancement of Science (AAAS)
14 publications, 0.74%
|
|
|
Oxford University Press
14 publications, 0.74%
|
|
|
AME Publishing Company
13 publications, 0.69%
|
|
|
American Society for Clinical Investigation
12 publications, 0.64%
|
|
|
SAGE
11 publications, 0.58%
|
|
|
Bentham Science Publishers Ltd.
10 publications, 0.53%
|
|
|
Public Library of Science (PLoS)
8 publications, 0.42%
|
|
|
Research Square Platform LLC
8 publications, 0.42%
|
|
|
Portland Press
7 publications, 0.37%
|
|
|
American Society of Hematology
7 publications, 0.37%
|
|
|
Mary Ann Liebert
5 publications, 0.26%
|
|
|
Annual Reviews
5 publications, 0.26%
|
|
|
Rockefeller University Press
5 publications, 0.26%
|
|
|
American Society of Clinical Oncology (ASCO)
4 publications, 0.21%
|
|
|
The Endocrine Society
3 publications, 0.16%
|
|
|
Impact Journals
3 publications, 0.16%
|
|
|
50
100
150
200
250
300
350
400
450
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
1.9k
Total citations:
1894
Citations from 2024:
676
(35.79%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Batlle E., Massague J. Transforming Growth Factor-β Signaling in Immunity and Cancer // Immunity. 2019. Vol. 50. No. 4. pp. 924-940.
GOST all authors (up to 50)
Copy
Batlle E., Massague J. Transforming Growth Factor-β Signaling in Immunity and Cancer // Immunity. 2019. Vol. 50. No. 4. pp. 924-940.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.immuni.2019.03.024
UR - https://doi.org/10.1016/j.immuni.2019.03.024
TI - Transforming Growth Factor-β Signaling in Immunity and Cancer
T2 - Immunity
AU - Batlle, Eduard
AU - Massague, Joan
PY - 2019
DA - 2019/04/16
PB - Elsevier
SP - 924-940
IS - 4
VL - 50
PMID - 30995507
SN - 1074-7613
SN - 1097-4180
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2019_Batlle,
author = {Eduard Batlle and Joan Massague},
title = {Transforming Growth Factor-β Signaling in Immunity and Cancer},
journal = {Immunity},
year = {2019},
volume = {50},
publisher = {Elsevier},
month = {apr},
url = {https://doi.org/10.1016/j.immuni.2019.03.024},
number = {4},
pages = {924--940},
doi = {10.1016/j.immuni.2019.03.024}
}
Cite this
MLA
Copy
Batlle, Eduard, and Joan Massague. “Transforming Growth Factor-β Signaling in Immunity and Cancer.” Immunity, vol. 50, no. 4, Apr. 2019, pp. 924-940. https://doi.org/10.1016/j.immuni.2019.03.024.